Topic: DAO deficiency: etiology, its different clinical manifestations, its dietary treatment, the regulatory framework, and any research project or innovation on the Diamine Oxidase (DAO) enzyme and its deficiency activity.
We invite scientists, academics, physicians, nutritionists, pharmacists, as well as professionals from the pharmaceutical and food industry to participate as International Experts on DAO deficiency by indicating the topic and content of their papers, whose abstract should be SUBMITTED before JULY 30, 2022. The proposed content will be reviewed by the scientific committee of the II International Congress of DAO Deficiency 2022.
The accepted papers will be broadcast live and simultaneously translated into different languages during the congress.
What is the current relevance of DAO deficiency?
For more than 20 years, DAO deficiency has been gaining great scientific, medical, pharmaceutical and nutritionist interest, as well as in the pharmaceutical and food industry, as evidenced by the increasing number of publications each year on this widespread metabolic disorder. It is estimated to affect 15% of the world’s population. Among the pathologies caused by DAO deficiency are neurological conditions such as migraine, gastrointestinal conditions such as irritable bowel disease, dermatological conditions such as dermatitis, dry skin and atopy, psychiatric conditions such as fibromyalgia and chronic fatigue, and psychological conditions such as Attention Deficit Hyperactivity Disorder (ADHD).
Numerous clinical studies have shown the positive effects of the use of the Diamine Oxidase (DAO) enzyme for the dietary management of pathologies associated with DAO deficiency. All this has led the European Commission to categorize the DAO enzyme as a Novel Food and the FDA as a GRAS.
This fruitful field of research, regulation and application of Diamine Oxidase enzyme deficiency justifies the need to extend the knowledge of this metabolic disorder in the scientific, medical, pharmaceutical and nutritionist community, as well as to extend its applications in the pharmaceutical and food industry, for better care of patients suffering from DAO deficiency. These are the objectives of the International Congress of DAO deficiency promoted every year by DR Healthcare.
Criteria for participation
The topics of interest of the papers should be related to basic and applied clinical research, as well as any other research and innovation content on DAO deficiency.
For those interested in participating as International Expert Speakers on DAO Deficiency for the International Congress of DAO Deficiency 2022, please contact us at firstname.lastname@example.org sending us your Curriculum Vitae and the topic you would like to address. The abstract of your presentation should be SUBMITTED by July 30, 2022. They will be reviewed and approved by the scientific committee of the II International Congress of DAO Deficiency 2022. We invite you to submit your original research articles and reviews for presentation at the International Congress. Feel free to contact us for further information or to determine if your papers are appropriate, or to assist you with other related questions.